Regina M. Young

4 ta ish

University of Pennsylvania

1. CRISPR-engineered T cells in patients with refractory cancer

   Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38

   MaqolaOAOchiq kirish20203 iqtibos

   ABIABI:AkademIndex/2026.other.102870

2. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

   Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando +34

   MaqolaOAOchiq kirish20182 iqtibos

   ABIABI:AkademIndex/2026.other.020493

3. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

   Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech +17

   MaqolaOAOchiq kirish20232 iqtibos

   ABIABI:AkademIndex/2026.other.102947

4. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

   Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons +35

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.475807